Verastem, Inc.
Verastem Oncology develops small molecule inhibitors targeting RAS/MAPK pathway-driven cancers.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 5Latest story
November 2026
October 2026
September 2026
August 2026
July 2026
Verastem Oncology develops small molecule inhibitors targeting RAS/MAPK pathway-driven cancers.
November 2026
October 2026
September 2026
August 2026
July 2026